-
22 years Chinese group follow-up revealed: smoking can double the risk of death from stomach cancer, long-term eating of garlic can play a preventive role.
Time of Update: 2020-07-18
the main outcome of this study was to assess the impact of lifestyle, vitamin and garlic supplementation on the incidence and mortality of gastric cancer, and the secondary outcome was to explore the progression of gastric lesions in participants between 1995 and 2003.
-
New Findings: Cold Spring Harbor Laboratory Study: Blocking cholesterol storage, which can stop pancreatic cancer cells from growing.
Time of Update: 2020-07-18
(image source: tobiloba Oni, Tueson laboratory / CSHL) cancer cells stopped proliferating when the researchers eliminated the soat1 enzyme through gene editing, preventing the cells from transforming and storing cholesterol.
-
i Hope College. Professor Qin Haifeng: Can patients who stop taking drugs due to adverse reactions challenge immunotherapy again?
Time of Update: 2020-07-18
today, we will talk about the patients who stop taking drugs due to adverse reactions, can they challenge immunotherapy again?
In case of severe Irae, re use of immunotherapy should be cautious and closely monitor the recurrence of Irae in related organs.
-
The Zhongbo team at Wuhan University found an important function and mechanism for ubiquitinase to regulate the immune and tumor occurrence of intestinal infections.
Time of Update: 2020-07-18
the expression level of USP25 in colon tissue or colon epithelial cells induced by bacterial infection and DSS was significantly increased, which indicated that intestinal infection inhibited host anti infection immune response by up regulating the expression of USP25.
-
Nat Cancer . . . The Zhongbo team found important results in the regulation of intestinal infection immunity and tumor occurrence by ubiquitinase.
Time of Update: 2020-07-18
in the model of Citrobacter ratus or Salmonella typhimurium infection, the expression levels of inflammatory cytokines and antimicrobial peptides in serum and intestinal tissue of USP25 knockout mice were significantly increased, resulting in stronger immune response and better inhibition of the replication of intestinal infection bacteria.
-
Nature Cancer: Chinese Academy of Sciences, nutrition institute Yu Huiyong and other discover the new mechanism to regulate liver cancer metabolism reprogramming.
Time of Update: 2020-07-18
on July 6, 2020, Yin Huiyong, Shanghai Institute of nutrition and health, Chinese Academy of Sciences, published online the latest research results entitled: aldolase B suppresses heparocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways.
-
NBE . . . Independent innovation: Huang Bo/Wang Ximo developed a new technology for the treatment of vesicle bile duct cancer.
Time of Update: 2020-07-18
on July 6, 2020, Huang Bo team of Institute of basic medicine, Chinese Academy of Medical Sciences and Wang Ximo's team from Tianjin Nankai Hospital Affiliated to Nankai University published in the journal Nature biomedical engineering the title "methotrexate loaded tumor cell derived microorganisms can relieve biliary obstruction in patients with external choledochocarcinoma This study not only demonstrated the efficacy and safety of drug loaded vesicle therapy for patients with cholangiocarcinoma, but also clarified its therapeutic mechanism.
-
Text - It's important to step on a bit and pick the data.
Time of Update: 2020-07-18
This is an article published in Journal of Philly in May. the main point of this paper is that researchers have constructed a feature which can predict the risk of recurrence of gastric cancer in stage II and stage III by means of absolute contraction and selection operator and Cox regression model, which can be used as a powerful tool for prognosis evaluation and help clinicians identify high-risk patients.
-
Express . . . Seek accelerated approval, innovative antibody conjugal drug treatment for cervical cancer Phase 2 clinical results are positive.
Time of Update: 2020-07-18
▎ Seattle genetics, editor of the content team of Wuxi apptec, recently announced that tisotumab vedotin, an innovative antibody coupled drug (ADC) jointly developed by the company and genmab company, has achieved positive top-line results in a potentially registered phase 2 clinical trial called innovatv204.
-
2020 version of NCCN and EAU prostate cancer guide important updates, experts to help you sum up!
Time of Update: 2020-07-18
second line treatment (first-line docetaxel): preferred scheme: abitiron (type 1), carbataxel (type 1), nzalutamide (type 1) specific regimen: mitoxantrone for palliative treatment with visceral metastasis symptoms that can not tolerate other treatments (type 2A), olapali (hrrm) (class 2b), pabolizumab (MSI-H or dmmr) (class 2b), radium-223 (bone metastasis) Other recommendations: consider docetaxel retreatment (category 2a), fine particle abietarone (class 2a), sipuleucel-t (category 2a), and other second-line hormone therapy (category 2a); delete: best supportive treatment.
-
Cancer Cell . . . A new approach to prostate cancer treatment: metabolic pathways and epigenetic swords.
Time of Update: 2020-07-18
however, little is known about the methylation of setd2 in non histone substrates, and the relationship between setd2 and EZH2 and its role in prostate cancer are not clear.
Fig. 2 the regulatory role of ampk-setd2-ezh2 signaling pathway in prostate cancer.
-
PNAS: Blocking a protein can inhibit liver and bile duct cancer.
Time of Update: 2020-07-18
this work is possible because researchers from the computer network information center (CNIC) of the Chinese Academy of sciences have developed an animal model, and changes in bile acid production have been shown to be responsible for this type of tumor.
-
Science Sub-journal: Immunotoxin spD-1 therapy offers new hope for this refractory cancer.
Time of Update: 2020-07-18
the team described the immune response in the treated patients and confirmed the same phenomenon in mouse models of mesothelioma and lung cancer, paving the way for larger clinical trials of combination therapy.
-
Professor JCO, Professor Zhou Caixuan, wrote that the efficacy of the second-line treatment of HER2 mutation SSCLC can be forsomed.
Time of Update: 2020-07-18
References: caicun Zhou et al, pyrotinib in HER2 mutant advanced lung adenocarcinoma after platinum based chemotherapy: a multicenter, open label, single arm, phase II study.j Clin Oncol.
-
A new type of targeted therapy for the idh-1 mutation of bile duct cancer.
Time of Update: 2020-07-18
at a median follow-up of 6.9 months, the median progression free survival (PFS; primary efficacy endpoint) of the ivosedenib group was better than that of the placebo group (2.7 months vs.
-
2020 EHA . . . China's CLL1-CD33 dual-target compound CAR-T was selected best-of-the-Theme, excellent efficacy. The doctor was bombarded with explosives.
Time of Update: 2020-07-18
and Dr. Liu Fang's icg144 trial is the first clinical trial of "cll1-cd33" dual target compound car-t in patients with relapsed / refractory acute myeloid leukemia (AML).
-
Canadian scientists have developed a new method that can deliver cancer drugs precisely to tumors.
Time of Update: 2020-07-18
recently, researchers from the University of Alberta, Canada, have modified nanoparticles to deliver anticancer drugs more accurately to colorectal cancer.
the title is "synthesis and analysis of 64Cu labeled ge11 modified polymeric mica nanoparticles for EGFR targeted molecular imaging in a colorectic cancer model".
-
CSCO Antily Lymphoma Alliance and Anti-Leukemia Alliance. The Youth Lymphoma Forum has come to a successful conclusion!
Time of Update: 2020-07-18
topic 1: progress in car-t cell therapy: Professor Zou Dehui, hematology hospital, Institute of Hematology, Chinese Academy of Medical Sciences, delivered a keynote speech and clinical practice and sharing on car-t cell therapy for refractory / relapsed non Hodgkin's lymphoma (NHL).
-
Science Sub-journal: CD28 double resistance enhances PD-1 anti-tumor effect and does not induce cytokine storms.
Time of Update: 2020-07-18
therefore, the dual antibody can be combined with the existing PD-1 immunotherapy to enhance the therapeutic effect of cancer and induce long-term anti-tumor immunity without inducing cytokine storm.
-
The inhibition of human osteosarcoma cells through the Wnt/beta-Catenin pathway.
Time of Update: 2020-07-18
in addition, the luciferase activity in the evo treated group was significantly lower than that in the untreated group, and the expression level of the corresponding pathway protein also proved that Evo played an anti-cancer role in osteosarcoma cells by inhibiting Wnt / β - catenin signaling pathway.
